Järvinen Tero A H, May Ulrike, Prince Stuart
School of Medicine, University of Tampere, 33520 Tampere, Finland.
Department of Orthopedics & Traumatology, Tampere University Hospital, 33520 Tampere, Finland.
Int J Mol Sci. 2015 Sep 30;16(10):23556-71. doi: 10.3390/ijms161023556.
Growth factors and other agents that could potentially enhance tissue regeneration have been identified, but their therapeutic value in clinical medicine has been limited for reasons such as difficulty to maintain bioactivity of locally applied therapeutics in the protease-rich environment of regenerating tissues. Although human diseases are treated with systemically administered drugs in general, all current efforts aimed at enhancing tissue repair with biological drugs have been based on their local application. The systemic administration of growth factors has been ruled out due to concerns about their safety. These concerns are warranted. In addition, only a small proportion of systemically administered drugs reach their intended target. Selective delivery of the drug to the target tissue and use of functional protein domains capable of penetrating cells and tissues could alleviate these problems in certain circumstances. We will present in this review a novel approach utilizing unique molecular fingerprints ("Zip/postal codes") in the vasculature of regenerating tissues that allows target organ-specific delivery of systemically administered therapeutic molecules by affinity-based physical targeting (using peptides or antibodies as an "address tag") to injured tissues undergoing repair. The desired outcome of targeted therapies is increased local accumulation and lower systemic concentration of the therapeutic payload. We believe that the physical targeting of systemically administered therapeutic molecules could be rapidly adapted in the field of regenerative medicine.
已经确定了可能促进组织再生的生长因子和其他因子,但其在临床医学中的治疗价值有限,原因包括难以在再生组织富含蛋白酶的环境中维持局部应用治疗药物的生物活性。虽然一般用全身给药的药物治疗人类疾病,但目前所有旨在用生物药物增强组织修复的努力都是基于局部应用。由于对生长因子安全性的担忧,已排除全身给药。这些担忧是有道理的。此外,全身给药的药物只有一小部分能到达预期靶点。在某些情况下,将药物选择性递送至靶组织以及使用能够穿透细胞和组织的功能性蛋白质结构域可以缓解这些问题。在本综述中,我们将介绍一种利用再生组织脉管系统中独特分子指纹(“邮政编码”)的新方法,该方法通过基于亲和力的物理靶向(使用肽或抗体作为“地址标签”)将全身给药的治疗分子靶向递送至正在修复的损伤组织,实现靶器官特异性递送。靶向治疗的理想结果是治疗有效载荷在局部的积累增加,全身浓度降低。我们相信,全身给药治疗分子的物理靶向在再生医学领域可以迅速得到应用。